0
New
New
2023
Neurodegenerative Drugs Market

Neurodegenerative Drugs Market

by Drug Class (Dopamine agonist , Decarboxylase inhibitors , Cholinesterase Inhibitors , Immunomodulators, Others ), by Indication (Parkinson’s Disease, Alzheimer’s Disease, Multiple Sclerosis , Others), by Distribution Channel (Hospital Pharmacies, Online Providers, Drug Stores and Retail Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031

Report Code: A13213
Mar 2023 | Pages: 300
Tables: 134
Charts: 76
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 

Neurodegenerative Drugs Market Research, 2031

The global neurodegenerative drugs market size was valued at $36,277.20 million in 2021 and is estimated to reach $74,809.38 million by 2031, growing at a CAGR of 7.5% from 2022 to 2031. Neurodegenerative drugs are the medications used to treat neurodegenerative diseases, which are conditions that result in progressive damage and degeneration of neurons in the brain and nervous system. These diseases include Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis (MS), and others. It is a group of conditions that are characterized by the progressive loss of neurons, leading to a decline in brain function and neurological symptoms. Neurodegeneration involves various aspects of neuronal structure and function, including the loss of axons, dendrites, synapses, and cell bodies, as well as the accumulation of abnormal proteins and other substances within neurons. Examples of neurodegenerative drugs include cholinesterase inhibitors (used to treat Alzheimer's disease), levodopa (used to treat Parkinson's disease), and interferon beta (used to treat multiple sclerosis).

The neurodegenerative drugs market was decreased during the lockdown period owing to decline in sales of drugs which can be used in treatment of Parkinson’s disease, and Alzheimer’s disease. In addition, many clinical trials for neurodegenerative drugs had delayed or postponed. This has resulted in a slowdown in the development of new drugs, which ultimately negatively impacted the growth of the market.

Neurodegenerative Drugs Market

“The neurodegenerative drugs market was decreased during the lockdown period owing to decline in sales of drugs which can be used in treatment of Parkinson’s disease, and Alzheimer’s disease. In addition, many clinical trials for neurodegenerative drugs had delayed or postponed. This has resulted in a slowdown in the development of new drugs, which ultimately negatively impacted the growth of the market.”

Market Dynamics

Increase in prevalence of neurodegenerative diseases such as Parkinson’s, multiple sclerosis and Alzheimer's disease which is expected to fuel the demand for drugs to treat these conditions. The growth of the neurodegenerative drugs market is expected to be driven by high potential in untapped, emerging markets, due to availability of improved healthcare infrastructure, and rise in prevalence of chronic diseases. Furthermore, the healthcare industry in emerging economies is developing at a significant rate, owing to rise in demand for enhanced healthcare services, and significant investments by government to improve healthcare infrastructure.

In addition, governments, pharmaceutical companies, and non-profit organizations are investing more in R&D for neurodegenerative drugs, leading to the development of new treatments and therapies which further supports the neurodegenerative drugs market growth.

Moreover, rise in awareness about the neurological disorders and the need for early diagnosis and treatment leading to a greater demand for drugs that can slow down or halt the progression of these diseases which is expected to contribute towards the growth of the market. E-commerce (electronic commerce) has become a vital tool for small and large businesses globally, due to rise in preference of consumers for online shopping over traditional purchasing methods. This is attributed to further supports growth of the neurodegenerative drugs market size.

Developing new drugs for neurodegenerative diseases is a complex and expensive process that requires significant investment in R&D. Thus, high costs of drug development limit the number of companies willing to invest in this area and limit the number of new drugs that come to market which hamper the growth of the neurodegenerative drugs market share. In addition, regulatory approval process for new drugs can be lengthy and expensive, which can limit the number of drugs that come to market and delay patient access to new treatments. Thus, high cost and complications associated with the neurodegenerative drugs hamper the growth of neurodegenerative drugs market share.

The COVID-19 had disrupted the workflows in the health care sector around the world. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of health care. The global neurodegenerative drugs market experienced a decline in 2020 due to global economic recession led by COVID-19. For instance, Biogen company which manufactured the neurodegenerative drugs had experienced the direct and indirect impact of the COVID-19 pandemic on business and operations, including sales, expense, supply chain, manufacturing, R&D costs, and clinical trials. Thus, the pandemic had a negative impact on the market growth.

However, pandemic has led to increased demand for treatments for neurological and psychiatric disorders, as many patients had experienced mental health issues as a result of the pandemic. This increased demand had led to a boost in sales for some neurodegenerative drugs which moderately drive the market growth.

Segmental Overview

The neurodegenerative drugs market is segmented into drug class, indication, distribution channel and region. By drug class, the market is categorized into dopamine agonists, decarboxylase inhibitors, cholinesterase inhibitors, immunomodulators and others. On the basis of indication, the market is segregated into Parkinson’s disease, Alzheimer's disease, multiple sclerosis, and others. By distribution channel, the market is classified into hospital pharmacies, drug store & retail pharmacies, and online providers. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Neurodegenerative Drugs Market

By Drug Class

The neurodegenerative drugs market is segmented into dopamine agonists, decarboxylase inhibitors, cholinesterase inhibitors, immunomodulators, and others. The others segment dominated the global market in 2021, owing to increase in prevalence of neurological conditions such as Parkinson's disease and the growing aging population as they are more prone to the neurological diseases. However, decarboxylase inhibitors segment is expected to register highest CAGR during the neurodegenerative drugs market forecast period. This is attributed to decarboxylase inhibitors help to reduce the side effects of dopamine replacement therapy by reducing the need for high doses of dopamine agonists.

Neurodegenerative Drugs Market

By Indication

The neurodegenerative drugs market is segregated into Parkinson’s disease, Alzheimer's disease, multiple sclerosis, and others. The multiple sclerosis segment dominated the global market in 2021. This was attributed to an increase in the number of people affected by multiple sclerosis. However, Parkinson's disease segment is expected to register highest CAGR during the forecast period. This is attributed to rise in prevalence of Parkinson’s disease. For instance, according to the Parkinson’s Foundation, 90,000 people in the U.S. diagnosed with Parkinson's every year. Thus, rise in prevalence of Parkinson’s disease is expected to drive the growth of the market.

Neurodegenerative Drugs Market

By Distribution Channel

The neurodegenerative drugs market is classified into hospital pharmacies, online providers, and drug store & retail pharmacies. The drug store & retail pharmacies held the largest market share in 2021 and is expected to remain dominant throughout the forecast period. This is attributed to the increase in number of patient suffering from neurological disorders including Parkinson’s and Alzheimer's which increases the demand for drugs in drug stores & retail pharmacies. However, online providers segment is expected to register the highest CAGR during the forecast period. This is attributed to convenient to use, lower prices, easy accessibility, and technological advancements.

Neurodegenerative Drugs Market

By Region

The neurodegenerative drugs market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for a major share of the neurodegenerative drugs market in 2021 and is expected to maintain its dominance during the forecast period.

Presence of several major players, such as AbbVie Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., and Viatris Inc manufactured the neurodegenerative drugs. However, governments and private organizations are investing heavily in R&D to develop new and effective neurodegenerative drugs led to the development of new therapies which supports the market growth. Furthermore, high purchasing power, and rise in adoption rate of neurodegenerative drugs are expected to drive the market growth. Moreover, product approvals, collaborations, and acquisitions adopted by the key players in this region boost the growth of the market.

Asia-Pacific is expected to grow at the highest rate during the forecast period. The market growth in this region is attributable to presence of pharmaceutical companies in the region as well as growth in the purchasing power of populated countries, such as China and India. In addition, rise in personalized medicine expenditure and adoption of neurodegenerative drugs to treat the diseases, drive the growth of the market. Furthermore, the Asia-Pacific region exhibits the largest medicine supply and the largest pharmaceuticals industry with availability of raw material in abundance, which can be easily accessed by manufacturers of neurodegenerative drugs. This, in turn, drives the growth of the neurodegenerative drugs industry.

Asia-Pacific offers profitable opportunities for key players operating in the neurodegenerative drugs industry, thereby registering the fastest growth rate during the forecast period, owing to the growing infrastructure of industries, rise in disposable incomes, as well as well-established presence of domestic companies in the region. In addition, the rise in contract manufacturing organizations within the region provides great opportunity for new entrants in this region.

Competition Analysis

Competitive analysis and profiles of the major players in the neurodegenerative drugs, such as AbbVie Inc., Biogen, F. Hoffmann-La Roche Ltd., Novartis AG, Orion Corporation, Sanofi, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and UCB S.A. are provided in this report. There are some other important players in the market such as SQUARE GROUP, Dr. Reddy's Laboratories Ltd., and others. Major players have adopted product approvals, acquisition and collaboration as key developmental strategies to improve the product portfolio of the neurodegenerative drugs market.

Recent Product Approvals in The Neurodegenerative Drugs Market

  • In June 2021, Biogen announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for ADUHELM (aducanumab-avwa) as the first and only Alzheimer’s disease treatment.
  • In October 2020, Novartis announced the U.S. Food and Drug Administration (FDA) has approved the fast-track designation for branaplam (LMI070) for the treatment of Huntington’s disease (HD).
  • In January 2020, Novartis announced the European Commission (EC) has approved Mayzent (siponimod) for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity.
  • In May 2020, Teva Pharmaceutical Industries Ltd. announced the China National Medical Products Administration (NMPA) has approved AUSTEDO (Deutetrabenazine Tablets) for the treatment of chorea associated with Huntington's disease (HD) and Tardive Dyskinesia (TD) in adults.

Acquisition In The Neurodegenerative Drugs Market

  • In March 2022, AbbVie Inc. announced that it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A).

Collaboration In The Neurodegenerative Drugs Market

  • In October 2021, Teva Pharmaceutical Industries Ltd. and MODAG GmbH announced a strategic collaboration for the development of MODAG's lead compound anle138b and a related compound, sery433. Teva received an exclusive global license to develop, manufacture and commercialize anle138b and sery433. The companies will jointly develop the compounds for the multiple system atrophy (MSA) and Parkinson’s disease (PD) indications based on early-stage clinical studies and consider exploring additional indications based on clinical outcomes.

Agreements In The Neurodegenerative Drugs Market

  • UCB S.A. announced that it has entered into a global co-development and co-commercialization agreement with Novartis covering UCB0599, a potential first in class, small molecule, alpha-synuclein misfolding inhibitor currently in Phase 2 clinical development, and upon completion of the ongoing Phase 1 program of UCB7853 for Parkinson’s Disease (PD).
  • UCB S.A. announced an agreement to enter into a world-wide, exclusive license agreement with Roche and Genentech, a member of the Roche Group, for the global development and commercialization of UCB0107 in Alzheimer’s Disease (AD).

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the neurodegenerative drugs market analysis from 2021 to 2031 to identify the prevailing neurodegenerative drugs market opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the neurodegenerative drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global neurodegenerative drugs market trends, key players, market segments, application areas, and market growth strategies.

Neurodegenerative Drugs Market Report Highlights

Aspects Details
Market Size By 2031 USD 74.8 billion
Growth Rate CAGR of 7.5%
Forecast period 2021 - 2031
Report Pages 300
By Drug Class
  • Dopamine agonist 
  • Decarboxylase inhibitors 
  • Cholinesterase Inhibitors 
  • Immunomodulators
  • Others 
By Indication
  • Parkinson’s Disease
  • Alzheimer’s Disease
  • Multiple Sclerosis 
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Online Providers
  • Drug Stores and Retail Pharmacies
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (Japan, China, Australia, India, South Korea, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players UCB S.A., Biogen, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi, Viatris Inc., Orion Corporation, Sun Pharmaceutical Industries Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd.

Analyst Review

This section provides various opinions of top-level CXOs in the global neurodegenerative drugs market. According to the insights of CXOs, the global neurodegenerative drugs market is expected to exhibit high growth potential attributable to high demand for neurodegenerative drugs and rise in pipeline products. However, availability of alternative treatment for neurodegenerative diseases and side effects of therapeutics hamper the market growth.?

CXOs further added that rise in number of product approvals for neurodegenerative drugs drive the market growth. Moreover, rise in awareness about Parkinson’s disease, Alzheimer's disease, increase in number of generic drug manufactures, and surge in ageing population are some factors which further boost the market growth. In addition, the presence of skilled neurologists and various diagnostic facilities for neurological disease patients are major factors which foster the growth of the market.??

Furthermore, North America is expected to witness the highest growth, in terms of revenue, owing to the increase in prevalence of neurodegenerative diseases along with rise in geriatric population and presence of key players in the region. However, Asia-Pacific is anticipated to witness notable growth, owing to rise in prevalence of neurological diseases and rise in R&D pipeline products for neurology field.

 
  • CHAPTER 1: INTRODUCTION

    • 1.1. Report description

    • 1.2. Key market segments

    • 1.3. Key benefits to the stakeholders

    • 1.4. Research Methodology

      • 1.4.1. Primary research

      • 1.4.2. Secondary research

      • 1.4.3. Analyst tools and models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET OVERVIEW

    • 3.1. Market definition and scope

    • 3.2. Key findings

      • 3.2.1. Top impacting factors

      • 3.2.2. Top investment pockets

    • 3.3. Porter’s five forces analysis

      • 3.3.1. Bargaining power of suppliers

      • 3.3.2. Bargaining power of buyers

      • 3.3.3. Threat of substitutes

      • 3.3.4. Threat of new entrants

      • 3.3.5. Intensity of rivalry

    • 3.4. Market dynamics

      • 3.4.1. Drivers

        • 3.4.1.1. Increase in prevalence of neurodegenerative diseases
        • 3.4.1.2. Initiatives by government and non-government organizations
        • 3.4.1.3. Expected launch of new drugs during the forecast period

      • 3.4.2. Restraints

        • 3.4.2.1. Complications associated with drug development

      • 3.4.3. Opportunities

        • 3.4.3.1. Increase in R&D activities

    • 3.5. COVID-19 Impact Analysis on the market

  • CHAPTER 4: NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS

    • 4.1. Overview

      • 4.1.1. Market size and forecast

    • 4.2. Dopamine agonist 

      • 4.2.1. Key market trends, growth factors and opportunities

      • 4.2.2. Market size and forecast, by region

      • 4.2.3. Market share analysis by country

    • 4.3. Decarboxylase inhibitors 

      • 4.3.1. Key market trends, growth factors and opportunities

      • 4.3.2. Market size and forecast, by region

      • 4.3.3. Market share analysis by country

    • 4.4. Cholinesterase Inhibitors 

      • 4.4.1. Key market trends, growth factors and opportunities

      • 4.4.2. Market size and forecast, by region

      • 4.4.3. Market share analysis by country

    • 4.5. Immunomodulators

      • 4.5.1. Key market trends, growth factors and opportunities

      • 4.5.2. Market size and forecast, by region

      • 4.5.3. Market share analysis by country

    • 4.6. Others 

      • 4.6.1. Key market trends, growth factors and opportunities

      • 4.6.2. Market size and forecast, by region

      • 4.6.3. Market share analysis by country

  • CHAPTER 5: NEURODEGENERATIVE DRUGS MARKET, BY INDICATION

    • 5.1. Overview

      • 5.1.1. Market size and forecast

    • 5.2. Parkinson’s Disease

      • 5.2.1. Key market trends, growth factors and opportunities

      • 5.2.2. Market size and forecast, by region

      • 5.2.3. Market share analysis by country

    • 5.3. Alzheimer’s Disease

      • 5.3.1. Key market trends, growth factors and opportunities

      • 5.3.2. Market size and forecast, by region

      • 5.3.3. Market share analysis by country

    • 5.4. Multiple Sclerosis 

      • 5.4.1. Key market trends, growth factors and opportunities

      • 5.4.2. Market size and forecast, by region

      • 5.4.3. Market share analysis by country

    • 5.5. Others

      • 5.5.1. Key market trends, growth factors and opportunities

      • 5.5.2. Market size and forecast, by region

      • 5.5.3. Market share analysis by country

  • CHAPTER 6: NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL

    • 6.1. Overview

      • 6.1.1. Market size and forecast

    • 6.2. Hospital Pharmacies

      • 6.2.1. Key market trends, growth factors and opportunities

      • 6.2.2. Market size and forecast, by region

      • 6.2.3. Market share analysis by country

    • 6.3. Online Providers

      • 6.3.1. Key market trends, growth factors and opportunities

      • 6.3.2. Market size and forecast, by region

      • 6.3.3. Market share analysis by country

    • 6.4. Drug Stores and Retail Pharmacies

      • 6.4.1. Key market trends, growth factors and opportunities

      • 6.4.2. Market size and forecast, by region

      • 6.4.3. Market share analysis by country

  • CHAPTER 7: NEURODEGENERATIVE DRUGS MARKET, BY REGION

    • 7.1. Overview

      • 7.1.1. Market size and forecast By Region

    • 7.2. North America

      • 7.2.1. Key trends and opportunities

      • 7.2.2. Market size and forecast, by Drug Class

      • 7.2.3. Market size and forecast, by Indication

      • 7.2.4. Market size and forecast, by Distribution Channel

      • 7.2.5. Market size and forecast, by country

        • 7.2.5.1. U.S.
          • 7.2.5.1.1. Key market trends, growth factors and opportunities
          • 7.2.5.1.2. Market size and forecast, by Drug Class
          • 7.2.5.1.3. Market size and forecast, by Indication
          • 7.2.5.1.4. Market size and forecast, by Distribution Channel
        • 7.2.5.2. Canada
          • 7.2.5.2.1. Key market trends, growth factors and opportunities
          • 7.2.5.2.2. Market size and forecast, by Drug Class
          • 7.2.5.2.3. Market size and forecast, by Indication
          • 7.2.5.2.4. Market size and forecast, by Distribution Channel
        • 7.2.5.3. Mexico
          • 7.2.5.3.1. Key market trends, growth factors and opportunities
          • 7.2.5.3.2. Market size and forecast, by Drug Class
          • 7.2.5.3.3. Market size and forecast, by Indication
          • 7.2.5.3.4. Market size and forecast, by Distribution Channel
    • 7.3. Europe

      • 7.3.1. Key trends and opportunities

      • 7.3.2. Market size and forecast, by Drug Class

      • 7.3.3. Market size and forecast, by Indication

      • 7.3.4. Market size and forecast, by Distribution Channel

      • 7.3.5. Market size and forecast, by country

        • 7.3.5.1. Germany
          • 7.3.5.1.1. Key market trends, growth factors and opportunities
          • 7.3.5.1.2. Market size and forecast, by Drug Class
          • 7.3.5.1.3. Market size and forecast, by Indication
          • 7.3.5.1.4. Market size and forecast, by Distribution Channel
        • 7.3.5.2. France
          • 7.3.5.2.1. Key market trends, growth factors and opportunities
          • 7.3.5.2.2. Market size and forecast, by Drug Class
          • 7.3.5.2.3. Market size and forecast, by Indication
          • 7.3.5.2.4. Market size and forecast, by Distribution Channel
        • 7.3.5.3. UK
          • 7.3.5.3.1. Key market trends, growth factors and opportunities
          • 7.3.5.3.2. Market size and forecast, by Drug Class
          • 7.3.5.3.3. Market size and forecast, by Indication
          • 7.3.5.3.4. Market size and forecast, by Distribution Channel
        • 7.3.5.4. Italy
          • 7.3.5.4.1. Key market trends, growth factors and opportunities
          • 7.3.5.4.2. Market size and forecast, by Drug Class
          • 7.3.5.4.3. Market size and forecast, by Indication
          • 7.3.5.4.4. Market size and forecast, by Distribution Channel
        • 7.3.5.5. Spain
          • 7.3.5.5.1. Key market trends, growth factors and opportunities
          • 7.3.5.5.2. Market size and forecast, by Drug Class
          • 7.3.5.5.3. Market size and forecast, by Indication
          • 7.3.5.5.4. Market size and forecast, by Distribution Channel
        • 7.3.5.6. Rest of Europe
          • 7.3.5.6.1. Key market trends, growth factors and opportunities
          • 7.3.5.6.2. Market size and forecast, by Drug Class
          • 7.3.5.6.3. Market size and forecast, by Indication
          • 7.3.5.6.4. Market size and forecast, by Distribution Channel
    • 7.4. Asia-Pacific

      • 7.4.1. Key trends and opportunities

      • 7.4.2. Market size and forecast, by Drug Class

      • 7.4.3. Market size and forecast, by Indication

      • 7.4.4. Market size and forecast, by Distribution Channel

      • 7.4.5. Market size and forecast, by country

        • 7.4.5.1. Japan
          • 7.4.5.1.1. Key market trends, growth factors and opportunities
          • 7.4.5.1.2. Market size and forecast, by Drug Class
          • 7.4.5.1.3. Market size and forecast, by Indication
          • 7.4.5.1.4. Market size and forecast, by Distribution Channel
        • 7.4.5.2. China
          • 7.4.5.2.1. Key market trends, growth factors and opportunities
          • 7.4.5.2.2. Market size and forecast, by Drug Class
          • 7.4.5.2.3. Market size and forecast, by Indication
          • 7.4.5.2.4. Market size and forecast, by Distribution Channel
        • 7.4.5.3. Australia
          • 7.4.5.3.1. Key market trends, growth factors and opportunities
          • 7.4.5.3.2. Market size and forecast, by Drug Class
          • 7.4.5.3.3. Market size and forecast, by Indication
          • 7.4.5.3.4. Market size and forecast, by Distribution Channel
        • 7.4.5.4. India
          • 7.4.5.4.1. Key market trends, growth factors and opportunities
          • 7.4.5.4.2. Market size and forecast, by Drug Class
          • 7.4.5.4.3. Market size and forecast, by Indication
          • 7.4.5.4.4. Market size and forecast, by Distribution Channel
        • 7.4.5.5. South Korea
          • 7.4.5.5.1. Key market trends, growth factors and opportunities
          • 7.4.5.5.2. Market size and forecast, by Drug Class
          • 7.4.5.5.3. Market size and forecast, by Indication
          • 7.4.5.5.4. Market size and forecast, by Distribution Channel
        • 7.4.5.6. Rest of Asia-Pacific
          • 7.4.5.6.1. Key market trends, growth factors and opportunities
          • 7.4.5.6.2. Market size and forecast, by Drug Class
          • 7.4.5.6.3. Market size and forecast, by Indication
          • 7.4.5.6.4. Market size and forecast, by Distribution Channel
    • 7.5. LAMEA

      • 7.5.1. Key trends and opportunities

      • 7.5.2. Market size and forecast, by Drug Class

      • 7.5.3. Market size and forecast, by Indication

      • 7.5.4. Market size and forecast, by Distribution Channel

      • 7.5.5. Market size and forecast, by country

        • 7.5.5.1. Brazil
          • 7.5.5.1.1. Key market trends, growth factors and opportunities
          • 7.5.5.1.2. Market size and forecast, by Drug Class
          • 7.5.5.1.3. Market size and forecast, by Indication
          • 7.5.5.1.4. Market size and forecast, by Distribution Channel
        • 7.5.5.2. Saudi Arabia
          • 7.5.5.2.1. Key market trends, growth factors and opportunities
          • 7.5.5.2.2. Market size and forecast, by Drug Class
          • 7.5.5.2.3. Market size and forecast, by Indication
          • 7.5.5.2.4. Market size and forecast, by Distribution Channel
        • 7.5.5.3. South Africa
          • 7.5.5.3.1. Key market trends, growth factors and opportunities
          • 7.5.5.3.2. Market size and forecast, by Drug Class
          • 7.5.5.3.3. Market size and forecast, by Indication
          • 7.5.5.3.4. Market size and forecast, by Distribution Channel
        • 7.5.5.4. Rest of LAMEA
          • 7.5.5.4.1. Key market trends, growth factors and opportunities
          • 7.5.5.4.2. Market size and forecast, by Drug Class
          • 7.5.5.4.3. Market size and forecast, by Indication
          • 7.5.5.4.4. Market size and forecast, by Distribution Channel
  • CHAPTER 8: COMPETITIVE LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top winning strategies

    • 8.3. Product Mapping of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Top player positioning, 2021

  • CHAPTER 9: COMPANY PROFILES

    • 9.1. Novartis AG

      • 9.1.1. Company overview

      • 9.1.2. Key Executives

      • 9.1.3. Company snapshot

      • 9.1.4. Operating business segments

      • 9.1.5. Product portfolio

      • 9.1.6. Business performance

      • 9.1.7. Key strategic moves and developments

    • 9.2. AbbVie Inc.

      • 9.2.1. Company overview

      • 9.2.2. Key Executives

      • 9.2.3. Company snapshot

      • 9.2.4. Operating business segments

      • 9.2.5. Product portfolio

      • 9.2.6. Business performance

      • 9.2.7. Key strategic moves and developments

    • 9.3. F. Hoffmann-La Roche Ltd.

      • 9.3.1. Company overview

      • 9.3.2. Key Executives

      • 9.3.3. Company snapshot

      • 9.3.4. Operating business segments

      • 9.3.5. Product portfolio

      • 9.3.6. Business performance

    • 9.4. Teva Pharmaceutical Industries Ltd.

      • 9.4.1. Company overview

      • 9.4.2. Key Executives

      • 9.4.3. Company snapshot

      • 9.4.4. Operating business segments

      • 9.4.5. Product portfolio

      • 9.4.6. Business performance

      • 9.4.7. Key strategic moves and developments

    • 9.5. Sanofi

      • 9.5.1. Company overview

      • 9.5.2. Key Executives

      • 9.5.3. Company snapshot

      • 9.5.4. Operating business segments

      • 9.5.5. Product portfolio

      • 9.5.6. Business performance

    • 9.6. Orion Corporation

      • 9.6.1. Company overview

      • 9.6.2. Key Executives

      • 9.6.3. Company snapshot

      • 9.6.4. Operating business segments

      • 9.6.5. Product portfolio

      • 9.6.6. Business performance

    • 9.7. Sun Pharmaceutical Industries Ltd.

      • 9.7.1. Company overview

      • 9.7.2. Key Executives

      • 9.7.3. Company snapshot

      • 9.7.4. Operating business segments

      • 9.7.5. Product portfolio

      • 9.7.6. Business performance

    • 9.8. UCB S.A.

      • 9.8.1. Company overview

      • 9.8.2. Key Executives

      • 9.8.3. Company snapshot

      • 9.8.4. Operating business segments

      • 9.8.5. Product portfolio

      • 9.8.6. Business performance

      • 9.8.7. Key strategic moves and developments

    • 9.9. Viatris Inc.

      • 9.9.1. Company overview

      • 9.9.2. Key Executives

      • 9.9.3. Company snapshot

      • 9.9.4. Operating business segments

      • 9.9.5. Product portfolio

      • 9.9.6. Business performance

    • 9.10. Biogen

      • 9.10.1. Company overview

      • 9.10.2. Key Executives

      • 9.10.3. Company snapshot

      • 9.10.4. Operating business segments

      • 9.10.5. Product portfolio

      • 9.10.6. Business performance

      • 9.10.7. Key strategic moves and developments

  • LIST OF TABLES

  • TABLE 01. GLOBAL NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 02. NEURODEGENERATIVE DRUGS MARKET FOR DOPAMINE AGONIST , BY REGION, 2021-2031 ($MILLION)
    TABLE 03. NEURODEGENERATIVE DRUGS MARKET FOR DECARBOXYLASE INHIBITORS , BY REGION, 2021-2031 ($MILLION)
    TABLE 04. NEURODEGENERATIVE DRUGS MARKET FOR CHOLINESTERASE INHIBITORS , BY REGION, 2021-2031 ($MILLION)
    TABLE 05. NEURODEGENERATIVE DRUGS MARKET FOR IMMUNOMODULATORS, BY REGION, 2021-2031 ($MILLION)
    TABLE 06. NEURODEGENERATIVE DRUGS MARKET FOR OTHERS , BY REGION, 2021-2031 ($MILLION)
    TABLE 07. GLOBAL NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 08. NEURODEGENERATIVE DRUGS MARKET FOR PARKINSON’S DISEASE, BY REGION, 2021-2031 ($MILLION)
    TABLE 09. NEURODEGENERATIVE DRUGS MARKET FOR ALZHEIMER’S DISEASE, BY REGION, 2021-2031 ($MILLION)
    TABLE 10. NEURODEGENERATIVE DRUGS MARKET FOR MULTIPLE SCLEROSIS , BY REGION, 2021-2031 ($MILLION)
    TABLE 11. NEURODEGENERATIVE DRUGS MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
    TABLE 12. GLOBAL NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 13. NEURODEGENERATIVE DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
    TABLE 14. NEURODEGENERATIVE DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
    TABLE 15. NEURODEGENERATIVE DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
    TABLE 16. NEURODEGENERATIVE DRUGS MARKET, BY REGION, 2021-2031 ($MILLION)
    TABLE 17. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 18. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 19. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 20. NORTH AMERICA NEURODEGENERATIVE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 21. U.S. NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 22. U.S. NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 23. U.S. NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 24. CANADA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 25. CANADA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 26. CANADA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 27. MEXICO NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 28. MEXICO NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 29. MEXICO NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 30. EUROPE NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 31. EUROPE NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 32. EUROPE NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 33. EUROPE NEURODEGENERATIVE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 34. GERMANY NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 35. GERMANY NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 36. GERMANY NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 37. FRANCE NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 38. FRANCE NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 39. FRANCE NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 40. UK NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 41. UK NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 42. UK NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 43. ITALY NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 44. ITALY NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 45. ITALY NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 46. SPAIN NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 47. SPAIN NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 48. SPAIN NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 49. REST OF EUROPE NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 50. REST OF EUROPE NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 51. REST OF EUROPE NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 52. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 53. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 54. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 55. ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 56. JAPAN NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 57. JAPAN NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 58. JAPAN NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 59. CHINA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 60. CHINA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 61. CHINA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 62. AUSTRALIA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 63. AUSTRALIA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 64. AUSTRALIA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 65. INDIA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 66. INDIA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 67. INDIA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 68. SOUTH KOREA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 69. SOUTH KOREA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 70. SOUTH KOREA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 71. REST OF ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 72. REST OF ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 73. REST OF ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 74. LAMEA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 75. LAMEA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 76. LAMEA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 77. LAMEA NEURODEGENERATIVE DRUGS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    TABLE 78. BRAZIL NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 79. BRAZIL NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 80. BRAZIL NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 81. SAUDI ARABIA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 82. SAUDI ARABIA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 83. SAUDI ARABIA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 84. SOUTH AFRICA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 85. SOUTH AFRICA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 86. SOUTH AFRICA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 87. REST OF LAMEA NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
    TABLE 88. REST OF LAMEA NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021-2031 ($MILLION)
    TABLE 89. REST OF LAMEA NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    TABLE 90. NOVARTIS AG: KEY EXECUTIVES
    TABLE 91. NOVARTIS AG: COMPANY SNAPSHOT
    TABLE 92. NOVARTIS AG: PRODUCT SEGMENTS
    TABLE 93. NOVARTIS AG: PRODUCT PORTFOLIO
    TABLE 94. NOVARTIS AG: KEY STRATERGIES
    TABLE 95. ABBVIE INC.: KEY EXECUTIVES
    TABLE 96. ABBVIE INC.: COMPANY SNAPSHOT
    TABLE 97. ABBVIE INC.: PRODUCT SEGMENTS
    TABLE 98. ABBVIE INC.: PRODUCT PORTFOLIO
    TABLE 99. ABBVIE INC.: KEY STRATERGIES
    TABLE 100. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
    TABLE 101. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
    TABLE 102. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
    TABLE 103. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
    TABLE 104. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
    TABLE 105. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
    TABLE 106. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
    TABLE 107. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
    TABLE 108. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
    TABLE 109. SANOFI: KEY EXECUTIVES
    TABLE 110. SANOFI: COMPANY SNAPSHOT
    TABLE 111. SANOFI: PRODUCT SEGMENTS
    TABLE 112. SANOFI: PRODUCT PORTFOLIO
    TABLE 113. ORION CORPORATION: KEY EXECUTIVES
    TABLE 114. ORION CORPORATION: COMPANY SNAPSHOT
    TABLE 115. ORION CORPORATION: PRODUCT SEGMENTS
    TABLE 116. ORION CORPORATION: PRODUCT PORTFOLIO
    TABLE 117. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
    TABLE 118. SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
    TABLE 119. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
    TABLE 120. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
    TABLE 121. UCB S.A.: KEY EXECUTIVES
    TABLE 122. UCB S.A.: COMPANY SNAPSHOT
    TABLE 123. UCB S.A.: PRODUCT SEGMENTS
    TABLE 124. UCB S.A.: PRODUCT PORTFOLIO
    TABLE 125. UCB S.A.: KEY STRATERGIES
    TABLE 126. VIATRIS INC.: KEY EXECUTIVES
    TABLE 127. VIATRIS INC.: COMPANY SNAPSHOT
    TABLE 128. VIATRIS INC.: PRODUCT SEGMENTS
    TABLE 129. VIATRIS INC.: PRODUCT PORTFOLIO
    TABLE 130. BIOGEN: KEY EXECUTIVES
    TABLE 131. BIOGEN: COMPANY SNAPSHOT
    TABLE 132. BIOGEN: PRODUCT SEGMENTS
    TABLE 133. BIOGEN: PRODUCT PORTFOLIO
    TABLE 134. BIOGEN: KEY STRATERGIES
  • LIST OF FIGURES

  • FIGURE 01. NEURODEGENERATIVE DRUGS MARKET, 2021-2031
    FIGURE 02. SEGMENTATION OF NEURODEGENERATIVE DRUGS MARKET, 2021-2031
    FIGURE 03. TOP INVESTMENT POCKETS IN NEURODEGENERATIVE DRUGS MARKET (2022-2031)
    FIGURE 04. HIGH BARGAINING POWER OF SUPPLIERS
    FIGURE 05. MODERATE BARGAINING POWER OF BUYERS
    FIGURE 06. LOW THREAT OF SUBSTITUTES
    FIGURE 07. MODERATE THREAT OF NEW ENTRANTS
    FIGURE 08. MODERATE INTENSITY OF RIVALRY
    FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALNEURODEGENERATIVE DRUGS MARKET
    FIGURE 10. NEURODEGENERATIVE DRUGS MARKET, BY DRUG CLASS, 2021(%)
    FIGURE 11. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR DOPAMINE AGONIST , BY COUNTRY 2021-2031(%)
    FIGURE 12. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR DECARBOXYLASE INHIBITORS , BY COUNTRY 2021-2031(%)
    FIGURE 13. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR CHOLINESTERASE INHIBITORS , BY COUNTRY 2021-2031(%)
    FIGURE 14. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR IMMUNOMODULATORS, BY COUNTRY 2021-2031(%)
    FIGURE 15. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR OTHERS , BY COUNTRY 2021-2031(%)
    FIGURE 16. NEURODEGENERATIVE DRUGS MARKET, BY INDICATION, 2021(%)
    FIGURE 17. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR PARKINSON’S DISEASE, BY COUNTRY 2021-2031(%)
    FIGURE 18. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR ALZHEIMER’S DISEASE, BY COUNTRY 2021-2031(%)
    FIGURE 19. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR MULTIPLE SCLEROSIS , BY COUNTRY 2021-2031(%)
    FIGURE 20. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
    FIGURE 21. NEURODEGENERATIVE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
    FIGURE 22. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021-2031(%)
    FIGURE 23. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021-2031(%)
    FIGURE 24. COMPARATIVE SHARE ANALYSIS OF NEURODEGENERATIVE DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2021-2031(%)
    FIGURE 25. NEURODEGENERATIVE DRUGS MARKET BY REGION, 2021
    FIGURE 26. U.S. NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 27. CANADA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 28. MEXICO NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 29. GERMANY NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 30. FRANCE NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 31. UK NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 32. ITALY NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 33. SPAIN NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 34. REST OF EUROPE NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 35. JAPAN NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 36. CHINA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 37. AUSTRALIA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 38. INDIA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 39. SOUTH KOREA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 40. REST OF ASIA-PACIFIC NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 41. BRAZIL NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 42. SAUDI ARABIA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 43. SOUTH AFRICA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 44. REST OF LAMEA NEURODEGENERATIVE DRUGS MARKET, 2021-2031 ($MILLION)
    FIGURE 45. TOP WINNING STRATEGIES, BY YEAR
    FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT
    FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY
    FIGURE 48. PRODUCT MAPPING OF TOP 10 PLAYERS
    FIGURE 49. COMPETITIVE DASHBOARD
    FIGURE 50. COMPETITIVE HEATMAP: NEURODEGENERATIVE DRUGS MARKET
    FIGURE 51. TOP PLAYER POSITIONING, 2021
    FIGURE 52. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
    FIGURE 53. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
    FIGURE 54. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
    FIGURE 55. ABBVIE INC.: NET REVENUE, 2019-2021 ($MILLION)
    FIGURE 56. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
    FIGURE 57. ABBVIE INC.: REVENUE SHARE BY REGION, 2021 (%)
    FIGURE 58. F. HOFFMANN-LA ROCHE LTD.: NET REVENUE, 2020-2022 ($MILLION)
    FIGURE 59. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
    FIGURE 60. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%)
    FIGURE 61. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
    FIGURE 62. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)
    FIGURE 63. SANOFI: NET REVENUE, 2019-2021 ($MILLION)
    FIGURE 64. SANOFI: RESEARCH & DEVELOPMENT EXPENDITURE, 2019-2021
    FIGURE 65. SANOFI: REVENUE SHARE BY SEGMENT, 2021 (%)
    FIGURE 66. SANOFI: REVENUE SHARE BY REGION, 2021 (%)
    FIGURE 67. ORION CORPORATION: NET SALES, 2020-2022 ($MILLION)
    FIGURE 68. ORION CORPORATION: REVENUE SHARE BY REGION, 2022 (%)
    FIGURE 69. SUN PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
    FIGURE 70. SUN PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY REGION, 2021 (%)
    FIGURE 71. UCB S.A.: NET SALES, 2020-2022 ($MILLION)
    FIGURE 72. UCB S.A.: REVENUE SHARE BY REGION, 2022 (%)
    FIGURE 73. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)
    FIGURE 74. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
    FIGURE 75. BIOGEN: NET REVENUE, 2019-2021 ($MILLION)
    FIGURE 76. BIOGEN: REVENUE SHARE BY REGION, 2021 (%)

 
 

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. Increase in prevalence of neurodegenerative diseases such as Alzheimer’s disease, multiple sclerosis, & Parkinson’s disease and rise in clinical trials for treatment of neurodegenerative diseases are the factors responsible for the market growth.

A. Parkinson’s disease is the leading application of Neurodegenerative Drugs Market.

A. North America is the largest regional market for Neurodegenerative Drugs.

A. The total market value of neurodegenerative drugs market is $36,277.2 million in 2021.

A. Top companies such as Novartis AG, F. Hoffmann-La Roche Ltd., AbbVie Inc., and Biogen held high market share in 2021.

A. Neurodegenerative drugs are used to treat neurodegenerative diseases that are designed to slow down the progression of the disease and/or relieve symptoms.

A. Asia-Pacific is expected to experience the growth rate of 9.2% during the forecast period, owing to surge in prevalence of disease such as Alzheimer’s disease, multiple sclerosis, & Parkinson’s disease, and rise in government initiatives for the management of neurodegenerative disease.

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Sample
RELATED TAGS

Purchase Full Report of
Neurodegenerative Drugs Market

Start reading instantly.
This Report and over 67,068+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,570
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Mar 2024 - Mar 2025)
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Mar 2024 - Mar 2025)
  • Single User
  • $5,730
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Mar 2024 - Mar 2025)
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Mar 2024 - Mar 2025)
  • Enterprise
    License/PDF

  • $9,600
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Mar 2024 - Mar 2025)
  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers